Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is ...

Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.

Structure Therapeutics has dropped over 55% as its GLP-1 pill targets obesity, yet analysts remain bullish with high price ...

With more people in Acadiana using GLP-1 medications like Ozempic and Wegovy to support their weight loss journeys, many are ...

The board-certified plastic and reconstructive surgeons at Ochsner Health are seeing a surge in patients seeking body ...

Novo Nordisk A/S (NYSE:NVO) is one of the Reddit Stocks with the Highest Upside Potential. On August 6, the company stated ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

State Treasurer Brad Briner has said the plan faced a $500 million deficit in 2026 without major changes. Increasing premiums ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America ...